Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT02292979 (BREACH Trial / EORTC-20113) (CLINICAL TRIAL / BRENTUXIMAB VEDOTIN / SGN-035 / ADCETRIS®)

Study Title
Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Hodgkin Lymphoma. (BREACH)(NCT02292979)

Trial Description
This study aims to evaluate the efficacy of brentuximab vedotin + AVD combination (doxorubicine, vinblastine, dacarbazine) in patients with Hodgkin lymphoma stage I / II with an unfavorable diagnosis, assessed by the negativity of PET (positron emission tomography) after two cycles of chemotherapy.

The BREACH (also known as LYSA/FIL/EORTC-20113) study in early stage HL patients, incorporating the anti -CD30 conjugate brentuximab vedotin in first-line treatment of unfavorable CSI/II disease (AVD-Br vs ABVD, followed by involved node radiotherapy or INRT). The primary goal is to improve the PET negativity after two cycles of chemotherapy. Next to the more common secondary end points (PFS, OS, CR rate after 2 cycles), researchers are very interested in the toxicity pattern of brentuximab vedotin in combination therapy.

This trial is sponsored by The Lymphoma Academic Research Organization (LYSARC) [1]

Study Data

Study Schematic

(CLINICAL TRIAL / BRENTUXIMAB VEDOTIN / SGN-035 / ADCETRIS®)

Click here to Return to Drug map


Last Editorial review: July 15, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015-2016 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar